Literature DB >> 29611557

Risk models to select high risk candidates for lung cancer screening.

Matthew B Schabath1,2.   

Abstract

Entities:  

Year:  2018        PMID: 29611557      PMCID: PMC5879506          DOI: 10.21037/atm.2018.01.12

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  15 in total

1.  Lung Cancer Screening With Low-Dose Computed Tomography in the United States-2010 to 2015.

Authors:  Ahmedin Jemal; Stacey A Fedewa
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777

2.  Indolent, Potentially Inconsequential Lung Cancers in the Pittsburgh Lung Screening Study.

Authors:  Prashanth M Thalanayar; Nejat Altintas; Joel L Weissfeld; Carl R Fuhrman; David O Wilson
Journal:  Ann Am Thorac Soc       Date:  2015-08

Review 3.  Screening for lung cancer.

Authors:  Renée Manser; Anne Lethaby; Louis B Irving; Christine Stone; Graham Byrnes; Michael J Abramson; Don Campbell
Journal:  Cochrane Database Syst Rev       Date:  2013-06-21

Review 4.  Application of risk prediction models to lung cancer screening: a review.

Authors:  Martin C Tammemägi
Journal:  J Thorac Imaging       Date:  2015-03       Impact factor: 3.000

5.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

6.  Overdiagnosis in low-dose computed tomography screening for lung cancer.

Authors:  Edward F Patz; Paul Pinsky; Constantine Gatsonis; Jorean D Sicks; Barnett S Kramer; Martin C Tammemägi; Caroline Chiles; William C Black; Denise R Aberle
Journal:  JAMA Intern Med       Date:  2014-02-01       Impact factor: 21.873

7.  Assessing the benefits and harms of low-dose computed tomography screening for lung cancer.

Authors:  Paul F Pinsky
Journal:  Lung Cancer Manag       Date:  2014

8.  Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval.

Authors:  Uraujh Yousaf-Khan; Carlijn van der Aalst; Pim A de Jong; Marjolein Heuvelmans; Ernst Scholten; Jan-Willem Lammers; Peter van Ooijen; Kristiaan Nackaerts; Carla Weenink; Harry Groen; Rozemarijn Vliegenthart; Kevin Ten Haaf; Matthijs Oudkerk; Harry de Koning
Journal:  Thorax       Date:  2016-06-30       Impact factor: 9.139

9.  Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.

Authors:  Martin C Tammemagi; Heidi Schmidt; Simon Martel; Annette McWilliams; John R Goffin; Michael R Johnston; Garth Nicholas; Alain Tremblay; Rick Bhatia; Geoffrey Liu; Kam Soghrati; Kazuhiro Yasufuku; David M Hwang; Francis Laberge; Michel Gingras; Sergio Pasian; Christian Couture; John R Mayo; Paola V Nasute Fauerbach; Sukhinder Atkar-Khattra; Stuart J Peacock; Sonya Cressman; Diana Ionescu; John C English; Richard J Finley; John Yee; Serge Puksa; Lori Stewart; Scott Tsai; Ehsan Haider; Colm Boylan; Jean-Claude Cutz; Daria Manos; Zhaolin Xu; Glenwood D Goss; Jean M Seely; Kayvan Amjadi; Harmanjatinder S Sekhon; Paul Burrowes; Paul MacEachern; Stefan Urbanski; Don D Sin; Wan C Tan; Natasha B Leighl; Frances A Shepherd; William K Evans; Ming-Sound Tsao; Stephen Lam
Journal:  Lancet Oncol       Date:  2017-10-18       Impact factor: 41.316

10.  Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.

Authors:  Kevin Ten Haaf; Jihyoun Jeon; Martin C Tammemägi; Summer S Han; Chung Yin Kong; Sylvia K Plevritis; Eric J Feuer; Harry J de Koning; Ewout W Steyerberg; Rafael Meza
Journal:  PLoS Med       Date:  2017-04-04       Impact factor: 11.069

View more
  2 in total

1.  Cancer Progress and Priorities: Lung Cancer.

Authors:  Matthew B Schabath; Michele L Cote
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-10       Impact factor: 4.254

2.  Melittin induces NSCLC apoptosis via inhibition of miR-183.

Authors:  Dongqi Gao; Jingjing Zhang; Lu Bai; Fubo Li; Yi Dong; Qingshan Li
Journal:  Onco Targets Ther       Date:  2018-08-01       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.